Abstract
Objective
To evaluate safety and efficacy of Peg-INF combined with ribavirin for genotype 4 infected children.
Methods
Seven children were included, five were infected parentrally, One vertically and one had both exposures. Clinical and laboratory evaluation were undertaken as well as quantitative PCR for HCV RNA before therapy at, 12, 24 and 52 weeks during treatment and one year after therapy. Liver biopsy was performed before and at the end of therapy. Four children had low and three had moderate viremia.
Results
At twelve weeks, two children (28.6%) lost viremia. Another child lost viremia at 52 weeks. ETR was 42.9%. During follow up one relapsed, thus SVR was 28.6%. Children with SVR were the youngest, their mean duration of infection was 4.5 vs 12.7 years in the others. Side effects of both INF & ribavirin was mild, required no reduction in doses.
Conclusion
Combination therapy of peg interferon-alpha with ribavirin is well tolerated in children and adolescents studied.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood born non-A, non-B viral hepatitis genome. Science 1998; 224:359–362.
Alter MJ, Kruszon-Moran D, Nainan OV, 1991. The prevelance of hepatitis C virus infection in the United States. 1988 through. N Engl J Med 1994; 341: 556–562.
Mostafa K. Mohamed. Epidemiology of HCV in Egypt. The Afro Arab Liver Journal 2004; 3: 41–52.
El Kamary S, Stoszek D, Strickland GT. 2004. Hepatitis C in Egypt: A concise Review, at conference program of AEAS.
Roudot Thoraval F, Pawlotsky JM, Thiers V. Lack of mother-to-infant transmission of hepatitis C virus in human immunodeficiency virus seronegative woman: a prospective study with hepatitis C virus RNA testing. Hepatology 1993; 17:772–777.
Moahmed MK, Magder LS, Abdel-Hamid M, El Daly M, Mikhail NN, Abdel-Aziz F, Medhat A, Thiers V, Strickland GT. Transmission of HCV between parents and children. Am J Trop Med Hyg 2006; 75: 16–20.
Wirth S, Pieper Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, Wintermeyer P, Jenke A. Peginterferon alfa - 2b plus ribavirin treatment in children and adolescent with chronic hepatitis C. Hepatology 2005; 41: 1013–1018.
Ishak KG, Amelia B, Leonardo B, Francesco C. Histological grading and staging of chronic hepatitis. J Hepatology 1995; 22: 696–699.
Herwig L, Andrea M, Johann D, Harald HK, Martin B. Interferon μ- and ribavirin in treating children and young adults with HCV after malignancy. Pediatrics 2000; 106: 53–56.
Lo Nigro L, la spina M, Mirabile E, Pisana P, Schiliro G, Guardo P. Use of Peg-interferon alfa 2-a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL. Pediatr Blood Cancer 2004; 4: 185.
FZ AL Faleh et al. Peginterferon alpha-2b plus ribavirin compared with INF alpha 2b plus ribavirin for initial treatment of chronic HCV in Saudi patients commenly infected with genotype 4. Liver International 2004; 24: 568–574.
Kamal SM, El Tawil AA, Nakano T, QHe, Rasenack J, Hakam SA. Peg INF alpha 2b and ribavirin therapy in chronic HCV genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858–866.
Moises D, Tarek H, Juan R, Andrew MAckrill, Farahad S. Optimized virological response in HCV genotype 4 with Peginterferon alpha 2a and ribavirin. Annals of Internal Medicine 2004; 140; 1: 72–73.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghaffar, T.Y.A., El Naghy, S., El Sebaie, H. et al. Pegylated α interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 76, 895–898 (2009). https://doi.org/10.1007/s12098-009-0187-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-009-0187-x